Drug news
EU CHMP recommends approval of Spectrila (asparaginase) for acute lymphoblastic leukaemia- Medac
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Spectrila (asparaginase), from Medac, for the treatment of acute lymphoblastic leukaemia. It is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adult patients.